We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Reduces Safety Reporting for Some Drug Trials
Draft Guidance Reduces Safety Reporting for Some Drug Trials
April 18, 2012
Drug sponsors may be able to collect less and better-targeted safety data in late-stage or postmarket trials if certain aspects of the safety profile are already well established, according to a new draft guidance.